Professional Medical Expertise Company (9574) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of Professional Medical Expertise Company stock SAR 87.05, price SAR 80.60, upside +8.0%, quality 51 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
39‑month range 60.12 SAR – 103.78 SAR · fair‑value band 57.31 SAR – 180.31 SAR · the 80.60 SAR price screens below the 87.05 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow Professional Medical Expertise in your weekly email
Every Wednesday you see whether Professional Medical Expertise is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Professional Medical Expertise Company engages in the retail sale of medical equipment, tools, supplies, and medical devices in the Kingdom of Saudi Arabia and the United Arab Emirates.
Show moreShow less
It offers products related to spine, sports medicine, pediatric orthopedic, general surgery, infection prevention, oncology, urology, minimal invasive surgery, cardiovascular, bariatric surgery, women's health, critical care, and diabetes, as well as dental care unit.
The company is also involved in medical devices and supplies; sales agents for pharmaceuticals; sale of orthopedic devices, medical equipment, and herbal medical preparations; devices; storage of medical devices and products, cosmetics, and pharmaceutical preparations; and manufacturers medical devices and products, and integrated administrative office services.
The company was formerly known as Socrates Specialized Trading Company and changed its name to Professional Medical Expertise Company in July 2012. Professional Medical Expertise Company was founded in 2010 and is headquartered in Jeddah, the Kingdom of Saudi Arabia.
Stock analysis
Professional Medical Expertise Company (9574) currently trades at 80.60 SAR, while our model-based Fair Value estimate is 87.05 SAR, so the stock looks roughly fairly valued today (gap 7.4%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 553.64 SAR per share, and 13 of the 17 models we run sit above the 80.60 SAR price.
Bear case: the Dividend Discount group reads lowest at 10.34 SAR, and 4 of the 17 models stay below the price. Data coverage for this calculation is high.
Scenario range: 57.31 SAR (bear) to 180.31 SAR (bull), the price of 80.60 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Professional Medical Expertise Company reported revenue of 419M SAR in FY2025 versus 131M SAR in FY2021, a compound +33.6%/yr. Reported net income was 41.7M SAR in FY2025, compounding +19.3%/yr from FY2021.
Key figures
Market cap 282M SAR (≈ $75.2M) Micro · P/E ratio 6.4 · P/S ratio 0.64 · EPS (TTM) 12.56 SAR · Dividend yield 1.2% · Net margin 10.0% · Return on equity 28.7% · Return on assets (EBIT) 13.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 8%, 9574 screens cheaper than that median.
Fair Value models
Bear57.31 SARFair Value 87.05 SARBull180.31 SAR
Price 80.60 SAR · Upside +8.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (10.43 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+33.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.3%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+31.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.9%
Dividend (yield on the price)1.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 14%
2025 sits 68% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Professional Medical Expertise Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 327 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+8.0% · Above median
Profitability
Return on equity (12 months)28.7% · Top 25%
Return on assets9.9% · Top 25%
Net margin (12 months)10.0% · Above median
Operating margin (12 months)14.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)11.9% · Above median
Dividend yield (12 months)1.2% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Professional Medical Expertise Company Fair Value". https://www.fairvalue-calculator.com/stock/9574
Frequently asked questions
Is Professional Medical Expertise Company (9574) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 87.05 SAR versus a price of 80.60 SAR, about +8% upside (fairly valued).
What is the fair value of 9574?
Our model-based fair value for Professional Medical Expertise Company is 87.05 SAR (as of Oct 29, 2026), built from audited fundamentals. The current price: 80.60 SAR.
What is the quality score of 9574?
Professional Medical Expertise Company has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Professional Medical Expertise Company (9574)?
Our model-based price target is the fair value of 87.05 SAR (as of Oct 29, 2026) from 17 valuation models. Cautious scenario 57.31 SAR, optimistic scenario 180.31 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Professional Medical Expertise Company stock forecast for 2026?
Our models put fair value at 87.05 SAR, about +8% upside versus a price of 80.60 SAR (fairly valued). Cautious scenario 57.31 SAR, optimistic scenario 180.31 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Professional Medical Expertise Company (9574)?
Professional Medical Expertise Company reported trailing-twelve-month revenue of about 441M SAR (latest available figure, as of Oct 29, 2026).
Does Professional Medical Expertise Company pay a dividend?
Professional Medical Expertise Company currently shows a dividend yield of 1.24% relative to its recent price (as of Oct 29, 2026).
What is the intrinsic value of Professional Medical Expertise Company (9574)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Professional Medical Expertise Company it is 87.05 SAR per share (as of Oct 29, 2026), against a price of 80.60 SAR. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Professional Medical Expertise Company stock overvalued or undervalued in 2026?
As of Oct 29, 2026, 9574 trades below its calculated fair value: price 80.60 SAR, fair value 87.05 SAR, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9574?
No. The price is what the market pays today (80.60 SAR); the fair value is what the company's own numbers justify (87.05 SAR). For Professional Medical Expertise Company the two are 6.45 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Professional Medical Expertise Company worth?
The market values Professional Medical Expertise Company at about 282M SAR (market capitalisation, as of Oct 29, 2026). Per share that is 80.60 SAR; our models calculate a fair value of 87.05 SAR per share.
What do the bullish and bearish scenarios say about 9574?
Our models span a range for Professional Medical Expertise Company: cautious scenario 57.31 SAR, base 87.05 SAR, optimistic 180.31 SAR per share (as of Oct 29, 2026, price 80.60 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9574?
Professional Medical Expertise Company trades at a price-to-earnings ratio of 6.4 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 87.05 SAR is built from several models across several years. Other multiples: P/B 1.9, P/S 0.6, EV/EBITDA 3.9.
How solid is the balance sheet of Professional Medical Expertise Company (9574)?
Balance-sheet figures for Professional Medical Expertise Company (as of Oct 29, 2026): return on equity 28.7%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 9574 from its 52-week high?
Professional Medical Expertise Company trades at 80.60 SAR, about 22% below its 52-week high of 102.90 SAR and 1% above the low of 80.00 SAR (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of 87.05 SAR is for.
Which stocks are comparable to Professional Medical Expertise Company?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Professional Medical Expertise Company stock attractive at the current price?
The data as of Oct 29, 2026: price 80.60 SAR, calculated fair value 87.05 SAR (+8%), Quality Score 51/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9574 calculated?
We run Professional Medical Expertise Company through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 87.05 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Professional Medical Expertise Company currently trades 7 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Professional Medical Expertise Company (9574)?
The closing price on Oct 29, 2026 was 80.60 SAR. Our model-based fair value is 87.05 SAR, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Professional Medical Expertise Company right now?
The model range is unusually wide (57.31 SAR to 180.31 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of Professional Medical Expertise Company
How large is the market capitalisation of Professional Medical Expertise Company (9574)?
The market capitalisation of Professional Medical Expertise Company is 282M SAR (≈ $75.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Professional Medical Expertise Company (9574)?
The price-to-sales ratio of Professional Medical Expertise Company is 0.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Professional Medical Expertise Company (9574)?
Earnings per share at Professional Medical Expertise Company are 12.56 SAR (price ÷ EPS = P/E 6.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Professional Medical Expertise Company (9574)?
The dividend yield of Professional Medical Expertise Company is 1.2% (payout 8.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Professional Medical Expertise Company (9574)?
The net margin of Professional Medical Expertise Company is 10.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Professional Medical Expertise Company (9574)?
The return on equity (ROE) of Professional Medical Expertise Company is 28.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Professional Medical Expertise Company (9574)?
On an EBIT basis the return on assets of Professional Medical Expertise Company is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Professional Medical Expertise Company (9574)?
The operating margin of Professional Medical Expertise Company is 14.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Professional Medical Expertise Company (9574)?
Revenue at Professional Medical Expertise Company is growing +11.9% versus a year earlier (3y avg +33.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Professional Medical Expertise Company (9574)?
Earnings per share at Professional Medical Expertise Company are growing +10.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Professional Medical Expertise Company (9574) generate?
The free cash flow of Professional Medical Expertise Company is −34.4M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Professional Medical Expertise Company (9574) carry?
The net debt of Professional Medical Expertise Company is 122M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Professional Medical Expertise Company in the live analysis
One click puts Professional Medical Expertise Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 29, 2026